The improper use of antimicrobials — from unnecessary prescriptions to incorrect dosing and duration — remains one of the primary drivers of Antimicrobial Resistance (AMR) and Multi-Drug-Resistant Organisms (MDROs). These resistance mechanisms increase morbidity and mortality by making infections harder to treat. With projections estimating up to 10 million deaths annually by 2050, AMR could soon become the leading global cause of death. For this reason, the World Health Organization (WHO) has identified AMR as one of the top ten global health threats of the future.
Antimicrobial stewardship programs have been developed to assist and educate healthcare professionals in counteracting this challenge. They promote rational antimicrobial use — preventing overuse, misuse, and unnecessary exposure to antibiotics, antifungals, antivirals, and antiparasitics — with the ultimate goal of slowing the spread of resistance. Recent antimicrobial resistance research consistently demonstrates that evidence-based antimicrobial stewardship programs are among the most effective strategies to limit resistance development and improve patient outcomes.
The concept of antimicrobial stewardship was first introduced in 1996 by John McGowan and Dale Gerding, who identified the connection between antimicrobial use and resistance, though early forms of stewardship programs were already being implemented in the 1970s.
Core principles of antimicrobial stewardship
The program is built upon key principles that continuously evolve to enhance efficiency, broaden reach, and integrate innovation into patient care. These principles are rooted in the five “D’s” of antimicrobial therapy — the right Drug, correct Dose, appropriate Drug-route, suitable Duration, and timely De-escalation — which guide every decision in antimicrobial management.
- Promote tailored, evidence-based antimicrobial use: the primary goal of antimicrobial stewardship is to ensure antimicrobials are used only when necessary and in the most effective way. This involves two essential components: conservation, deciding when antimicrobials should or should not be prescribed, and optimization, determining how to use them appropriately to achieve the best outcomes.
- Develop and distribute rapid diagnostic technologies: rapid and accurate diagnostics are crucial for directing antimicrobial therapy. Tools such as MALDI-TOF mass spectrometry, molecular biology techniques, AI-based systems, and automated antimicrobial susceptibility testing (AST) enable clinicians to identify pathogens and resistance profiles faster, reducing reliance on empirical therapies and supporting earlier de-escalation.
- Minimize therapy duration: prolonged antimicrobial treatments contribute to the development of resistance. Stewardship programs therefore emphasize shorter, evidence-based treatment durations for many common infections, balancing efficacy with reduced selective pressure on pathogens.
Joint Efforts for Common Objectives
For antimicrobial stewardship to be truly effective, it must rely on a collaborative and multidisciplinary approach that brings together expertise from different areas of healthcare. The success of stewardship programs depends on the coordinated work of several key contributors:
- Physicians play a central role in selecting the most appropriate antimicrobial therapies, interpreting microbiology results, and managing complex cases involving resistant organisms.
- Microbiologists ensure the accurate and timely identification of pathogens and their susceptibility profiles. They collaborate closely with clinicians to interpret laboratory data and refine testing strategies that guide treatment decisions.
- Infection prevention and control teams help limit the spread of resistant organisms through surveillance, isolation procedures, and staff education. They also work alongside stewardship teams to contain outbreaks of multi-drug-resistant organisms (MDROs).
- Patients represent an often-overlooked but essential component of the process. By understanding the risks of antibiotic misuse and the importance of completing prescribed treatments, patients actively contribute to reducing antibiotic resistance and improving public health outcomes.
Technological tools empowering antimicrobial stewardship
Novel technologies have the potential to improve the efficiency and effectiveness of Antimicrobial Stewardship programs. First, let’s consider data handling and interpretation: from electronic health records that enable real-time monitoring of antimicrobial prescriptions and patient outcomes to surveillance systems that track antimicrobial use and resistance trends at both the institutional and regional levels, these tools help identify emerging resistance patterns and facilitate prompt action when necessary. From a diagnostic perspective, rapid diagnostic tools can reduce the time needed for pathogen identification and susceptibility results. Of course, this can enable earlier specific therapy, de-escalation, or discontinuation of treatment. Rapid diagnostics for Antimicrobial Susceptibility Testing (AST) is the primary diagnostic assay that tests an antimicrobial agent’s ability to inhibit bacterial growth (in vitro under standardized conditions) to guide the selection of the best antimicrobial therapy for each patient. However, results typically take a few days after sampling, and when selecting the appropriate antibiotic is critical to prevent the emergence of MDROs and ensure patient survival, this delay cannot be overlooked. New EUCAST frameworks, rapid workflows, and automation have been developed specifically for this purpose: providing faster results than traditional manual methods, allowing for quicker therapy adjustments and potentially better patient outcomes.
And that’s not all. Other emerging tools, such as telemedicine and AI-powered predictive analytics, aim to support Antimicrobial Stewardship by enabling remote consultations, identifying resistance patterns, forecasting outbreaks, and guiding personalized antibiotic therapies through the analysis of large-scale clinical and epidemiological data. AI also advances the development of diagnostic tools, reducing reliance on broad-spectrum antibiotics and enabling timely, targeted treatments.
Novel technologies are transforming the efficiency and precision of antimicrobial stewardship programs.
Effective data management is the first crucial step: electronic health records and advanced surveillance systems now allow real-time monitoring of prescriptions, patient outcomes, and resistance trends at institutional and regional levels. These tools make it possible to detect emerging resistance patterns early and enable timely intervention.
From a diagnostic perspective, rapid diagnostic tools are revolutionizing how pathogens and their susceptibility profiles are identified. In particular, Antimicrobial Susceptibility Testing (AST) assesses a drug’s ability to inhibit bacterial growth under standardized conditions, guiding clinicians toward the most effective therapy for each patient.
Although traditional AST results can take several days, new EUCAST frameworks, automated workflows, and laboratory automation are significantly reducing turnaround times, enabling faster therapeutic decisions and improving patient outcomes.
Beyond diagnostics, AI-driven predictive analytics and telemedicine are emerging as powerful allies in antimicrobial stewardship. These technologies enable remote consultations, predict resistance patterns, forecast outbreaks, and support personalized antibiotic therapy by analyzing large-scale clinical and epidemiological data.
Artificial intelligence is also accelerating the development of diagnostic solutions, helping clinicians move away from broad-spectrum antibiotic use toward timely, targeted treatments.
Global frameworks supporting antimicrobial stewardship
Numerous international and national organizations have established guidelines and frameworks to support the implementation of effective stewardship programs:
- World Health Organization (WHO). The WHO provides global guidance on antimicrobial stewardship, emphasizing the importance of developing national action plans and implementing integrated surveillance systems.
- Centers for Disease Control and Prevention (CDC). The CDC’s Core Elements of Hospital Antibiotic Stewardship Programs outline essential components for successful stewardship. These include leadership commitment, accountability, drug expertise, action, tracking, reporting, and education. Additionally, this Organization leads the Be Antibiotics Aware campaign. The goal? Improve antibiotic prescribing and use, and combat Antibiotic Resistance.
- European Centre for Disease Prevention and Control (ECDC). The ECDC promotes prudent antibiotic use across Europe through initiatives such as European Antibiotic Awareness Day (held annually on November 18) and guidance on antimicrobial use in both human and veterinary medicine.
Other significant initiatives include the European Study Group for Antibiotic Policies (ESGAP), which fosters education and research through a collaborative virtual community, and ATLAS, a searchable global database aggregating antibacterial surveillance data from multiple international programs.
ATLAS serves as an invaluable tool for healthcare professionals, enabling detailed data evaluation and analysis to support clinical decision-making and global resistance monitoring. Together, these frameworks promote a unified approach to optimizing antimicrobial use, enhancing surveillance, and mitigating the growing threat of resistance worldwide.
Challenges and future perspectives in antimicrobial stewardship
Integrating antimicrobial stewardship into everyday clinical workflows allows healthcare institutions to reduce inappropriate antibiotic use, lower resistance-related costs, prevent the emergence of resistant pathogens, and improve patient safety. Despite these clear benefits, several challenges still limit the widespread adoption of stewardship programs — including scarce resources, limited access to rapid diagnostics, and uneven implementation across healthcare systems.
While stewardship initiatives have successfully optimized antibiotic use in high-income countries, progress remains limited in developing regions, where the burden of antimicrobial resistance continues to grow. This makes it urgent to establish, implement, and evaluate effective stewardship frameworks on a global scale. As traditional antibiotics gradually lose their efficacy, the response to AMR must involve coordinated actions at multiple levels: infection prevention, optimized treatment protocols, new drug development, policy reform, and strong international collaboration.
Ultimately, every healthcare professional — from hospital clinicians to microbiologists and community practitioners — plays a vital role in combating antimicrobial resistance. Building effective stewardship programs is not just a professional duty but a shared global responsibility.
Bibliography
- Shrestha J, Zahra F, Cannady Jr P. Antimicrobial Stewardship. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
- Yoo JH. Antimicrobial Resistance – The “Real” Pandemic We Are Unaware Of, Yet Nearby. J Korean Med Sci. 2025 May 19;40(19):e161.
- Majumder MAA, Rahman S, Cohall D, et al. Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health. Infect Drug Resist. 2020 Dec 29;13:4713–4738.
- Pennisi F, Pinto A, Ricciardi GE, et al. The Role of Artificial Intelligence and Machine Learning Models in Antimicrobial Stewardship in Public Health: A Narrative Review. Antibiotics. 2025;14(2):134.
Join CoScience HUB
Create your CoScience HUB account now to access cutting-edge science and position yourself at the forefront of innovation.
Sign Up Now
